Peter Chockley1, Sagar L Patil1, Stephen Gottschalk2. 1. Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. 2. Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Electronic address: stephen.gottschalk@stjude.org.
Abstract
BACKGROUND AIMS: Vesicular stomatitis virus G (VSV-G)-pseudotyped lentiviral vectors (LVs) are widely used to reliably generate genetically modified, clinical-grade T-cell products. However, the results of genetically modifying natural killer (NK) cells with VSV-G LVs have been variable. The authors explored whether inhibition of the IKK-related protein kinases TBK1 and IKKε, key signaling molecules of the endosomal TLR4 pathway, which is activated by VSV-G, would enable the reliable transduction of NK cells by VSV-G LVs. METHODS: The authors activated NK cells from peripheral blood mononuclear cells using standard procedures and transduced them with VSV-G LVs encoding a marker gene (yellow fluorescent protein [YFP]) or functional genes (chimeric antigen receptors [CARs], co-stimulatory molecules) in the presence of three TBK1/IKKε inhibitors (MRT67307, BX-795, amlexanox). NK cell transduction was evaluated by flow cytometry and/or western blot and the functionality of expressed CARs was evaluated in vitro. RESULTS: Blocking TBK1/IKKε during transduction of NK cells enabled their efficient transduction by VSV-G LVs as judged by YFPexpression of 40-50%, with half maximal effective concentrations of 1.1 µM (MRT67307), 5 µM (BX-795) and 24.8 µM (amlexanox). Focusing on MRT67307, the authors successfully generated NK cells expressing CD19-CARs or HER2-CARs with an inducible co-stimulatory molecule. CAR NK cells exhibited increased cytolytic activity and ability to produce cytokines in comparison to untreated controls, confirming CAR functionality. CONCLUSIONS: The authors demonstrate that inhibition of TBK1/IKKε enables the reliable generation of genetically modified NK cells using VSV-G LVs. The authors' protocol can be readily adapted to generate clinical-grade NK cells and thus has the potential to facilitate the clinical evaluation of genetically modified NK cell-based therapeutics in the future.
BACKGROUND AIMS: Vesicular stomatitis virus G (VSV-G)-pseudotyped lentiviral vectors (LVs) are widely used to reliably generate genetically modified, clinical-grade T-cell products. However, the results of genetically modifying natural killer (NK) cells with VSV-G LVs have been variable. The authors explored whether inhibition of the IKK-related protein kinases TBK1 and IKKε, key signaling molecules of the endosomal TLR4 pathway, which is activated by VSV-G, would enable the reliable transduction of NK cells by VSV-G LVs. METHODS: The authors activated NK cells from peripheral blood mononuclear cells using standard procedures and transduced them with VSV-G LVs encoding a marker gene (yellow fluorescent protein [YFP]) or functional genes (chimeric antigen receptors [CARs], co-stimulatory molecules) in the presence of three TBK1/IKKε inhibitors (MRT67307, BX-795, amlexanox). NK cell transduction was evaluated by flow cytometry and/or western blot and the functionality of expressed CARs was evaluated in vitro. RESULTS: Blocking TBK1/IKKε during transduction of NK cells enabled their efficient transduction by VSV-G LVs as judged by YFPexpression of 40-50%, with half maximal effective concentrations of 1.1 µM (MRT67307), 5 µM (BX-795) and 24.8 µM (amlexanox). Focusing on MRT67307, the authors successfully generated NK cells expressing CD19-CARs or HER2-CARs with an inducible co-stimulatory molecule. CAR NK cells exhibited increased cytolytic activity and ability to produce cytokines in comparison to untreated controls, confirming CAR functionality. CONCLUSIONS: The authors demonstrate that inhibition of TBK1/IKKε enables the reliable generation of genetically modified NK cells using VSV-G LVs. The authors' protocol can be readily adapted to generate clinical-grade NK cells and thus has the potential to facilitate the clinical evaluation of genetically modified NK cell-based therapeutics in the future.
Authors: Vladimir V Kravchenko; John C Mathison; Klaus Schwamborn; Frank Mercurio; Richard J Ulevitch Journal: J Biol Chem Date: 2003-05-06 Impact factor: 5.157
Authors: Shannon M Reilly; Shian-Huey Chiang; Stuart J Decker; Louise Chang; Maeran Uhm; Martha J Larsen; John R Rubin; Jonathan Mowers; Nicole M White; Irit Hochberg; Michael Downes; Ruth T Yu; Christopher Liddle; Ronald M Evans; Dayoung Oh; Pingping Li; Jerrold M Olefsky; Alan R Saltiel Journal: Nat Med Date: 2013-02-10 Impact factor: 53.440
Authors: W K Chan; D Suwannasaen; R E Throm; Y Li; P W Eldridge; J Houston; J T Gray; C-H Pui; W Leung Journal: Leukemia Date: 2014-06-03 Impact factor: 11.528
Authors: Matthew Bauler; Jessica K Roberts; Chang-Chih Wu; Baochang Fan; Francesca Ferrara; Bon Ham Yip; Shiyong Diao; Young-In Kim; Jennifer Moore; Sheng Zhou; Matthew M Wielgosz; Byoung Ryu; Robert E Throm Journal: Mol Ther Methods Clin Dev Date: 2019-11-26 Impact factor: 6.698
Authors: Brooke Prinzing; Caitlin C Zebley; Christopher T Petersen; Yiping Fan; Alejandro Allo Anido; Zhongzhen Yi; Phuong Nguyen; Haley Houke; Matthew Bell; Dalia Haydar; Charmaine Brown; Shannon K Boi; Shanta Alli; Jeremy Chase Crawford; Janice M Riberdy; Jeoungeun J Park; Sheng Zhou; Mireya Paulina Velasquez; Chris DeRenzo; Cicera R Lazzarotto; Shengdar Q Tsai; Peter Vogel; Shondra M Pruett-Miller; Deanna M Langfitt; Stephen Gottschalk; Ben Youngblood; Giedre Krenciute Journal: Sci Transl Med Date: 2021-11-17 Impact factor: 17.956